乱用薬物市場：パイプラインレポート（開発段階、セグメント、地域・国、規制経路、主要企業）、2022年最新版

当レポートでは、乱用薬物市場について調査し、製品概要と開発中のパイプライン製品動向、参入企業の最近の動向などを提供しています。

目次

第1章 目次

第2章 イントロダクション

• 乱用薬物の概要

第3章 開発中の製品

• 乱用薬物- 開発段階別のパイプライン製品
• 乱用薬物- 地域別のパイプライン製品
• 乱用薬物- 規制経路別のパイプライン製品
• 乱用薬物- 推定承認日別のパイプライン製品

第4章 乱用薬物- 企業が開発中のパイプライン製品

• 乱用薬物企業- 開発段階別のパイプライン製品
• 乱用薬物- 開発段階別のパイプライン製品

第5章 乱用薬物の企業と製品概要

• Accelerate Diagnostics Inc
• Adaltis Srl
• Banyan Biomarkers Inc
• Behavioral Diagnostics Inc
• BioMark Technologies Inc
• Ceres Nanosciences Inc
• genedrive plc
• Horiba Ltd
• OpalGenix Inc
• Randox Laboratories Ltd
• Roche Diagnostics International Ltd
• SDI Biomed, Inc
• SensoDXII LLC
• Siemens Healthcare Diagnostics Inc
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• University of California San Francisco
• ZORA Biosciences Oy

第6章 乱用薬物- 最近の開発

第7章 付録

• 調査手法
• GlobalDataについて
• お問合せ
• 免責事項

List of Tables

List of Tables

• Drugs of Abuse - Pipeline Products by Stage of Development
• Drugs of Abuse - Pipeline Products by Territory
• Drugs of Abuse - Pipeline Products by Regulatory Path
• Drugs of Abuse - Pipeline Products by Estimated Approval Date
• Drugs of Abuse Companies - Pipeline Products by Stage of Development
• Drugs of Abuse - Pipeline Products by Stage of Development
• Accelerate Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
• Accelerate Pheno System - Intra-Abdominal Infections Assay - Product Status
• Accelerate Pheno System - Intra-Abdominal Infections Assay - Product Description
• Accelerate Pheno System - Urinary Tract Infections Assay - Product Status
• Accelerate Pheno System - Urinary Tract Infections Assay - Product Description
• Adaltis Srl Pipeline Products & Ongoing Clinical Trials Overview
• CLIAgen Steroid Assay - Product Status
• CLIAgen Steroid Assay - Product Description
• Banyan Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview
• Diagnostic Assay - Alcoholism - Product Status
• Diagnostic Assay - Alcoholism - Product Description
• Behavioral Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
• Epigenetic Test - Alcohol Abstinence - Product Status
• Epigenetic Test - Alcohol Abstinence - Product Description
• BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
• ABA-SUBSTANCE - Product Status
• ABA-SUBSTANCE - Product Description
• Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
• Nanotrap Fentanyl Assay - Product Status
• Nanotrap Fentanyl Assay - Product Description
• genedrive plc Pipeline Products & Ongoing Clinical Trials Overview
• Genedrive - OPRM1 Assay - Product Status
• Genedrive - OPRM1 Assay - Product Description
• Horiba Ltd Pipeline Products & Ongoing Clinical Trials Overview
• Pentra C200 Analyzer - DAU Assay - Product Status
• Pentra C200 Analyzer - DAU Assay - Product Description
• OpalGenix Inc Pipeline Products & Ongoing Clinical Trials Overview
• GPS-Opioid - Product Status
• GPS-Opioid - Product Description
• Randox Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview
• Rx Daytona - Oxycodone Assay - Product Status
• Rx Daytona - Oxycodone Assay - Product Description
• Rx Daytona - Propoxyphene Assay - Product Status
• Rx Daytona - Propoxyphene Assay - Product Description
• RX Imola Cotinine Test - Product Status
• RX Imola Cotinine Test - Product Description
• RX Imola Oxycodone Test - Product Status
• RX Imola Oxycodone Test - Product Description
• RX Imola Propoxyphene Test - Product Status
• RX Imola Propoxyphene Test - Product Description
• Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
• Chromate (SV) Assay - Product Status
• Chromate (SV) Assay - Product Description
• Oxidant (SV) Assay - Product Status
• Oxidant (SV) Assay - Product Description
• pH Assay - Product Status
• pH Assay - Product Description
• Specific Gravity Assay - Product Status
• Specific Gravity Assay - Product Description
• THC Oral Fluid Assay - Product Status
• THC Oral Fluid Assay - Product Description
• SDI Biomed, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• SDI CA 480 - Drugs Of Abuse Assay - Product Status
• SDI CA 480 - Drugs Of Abuse Assay - Product Description
• SensoDXII LLC Pipeline Products & Ongoing Clinical Trials Overview
• SensoDx Drug Screen - Product Status
• SensoDx Drug Screen - Product Description
• Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
• Dimension RxL Max Test - Meperidine - Product Status
• Dimension RxL Max Test - Meperidine - Product Description
• Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview
• Dimension RxL Max Test - Oxycodone - Product Status
• Dimension RxL Max Test - Oxycodone - Product Description
• Dimension RxL Max Test - Tramadol - Product Status
• Dimension RxL Max Test - Tramadol - Product Description
• Viva-E Drug Testing System - Syva Emit DAT 6 Acetyl Morphine Assay - Product Status
• Viva-E Drug Testing System - Syva Emit DAT 6 Acetyl Morphine Assay - Product Description
• Viva-Jr Drug Testing System - Syva Emit DAT 6 Acetyl Morphine Assay - Product Status
• Viva-Jr Drug Testing System - Syva Emit DAT 6 Acetyl Morphine Assay - Product Description
• Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview
• Cascadion SM Clinical Analyzer - Drugs Of Abuse Assay - Product Status
• Cascadion SM Clinical Analyzer - Drugs Of Abuse Assay - Product Description
• University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
• Steroid Detection Assay - Product Status
• Steroid Detection Assay - Product Description
• ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview
• Statin Intolerance Risk Test - Product Status
• Statin Intolerance Risk Test - Product Description
• Glossary

List of Figures

List of Figures

• Drugs of Abuse - Pipeline Products by Stage of Development
• Drugs of Abuse - Pipeline Products by Territory
• Drugs of Abuse - Pipeline Products by Regulatory Path
• Drugs of Abuse - Pipeline Products by Estimated Approval Date

GlobalData's Medical Devices sector report, "Drugs of Abuse Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the Drugs of Abuse pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Drugs of Abuse Tests are used for the detection of illegal and/or prescribed substances in the patient samples including urine, blood, saliva, or sweat.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the Drugs of Abuse under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Drugs of Abuse and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Drugs of Abuse under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 Drugs of Abuse Overview

3 Products under Development

• 3.1 Drugs of Abuse - Pipeline Products by Stage of Development
• 3.2 Drugs of Abuse - Pipeline Products by Territory
• 3.3 Drugs of Abuse - Pipeline Products by Regulatory Path
• 3.4 Drugs of Abuse - Pipeline Products by Estimated Approval Date

4 Drugs of Abuse - Pipeline Products under Development by Companies

• 4.1 Drugs of Abuse Companies - Pipeline Products by Stage of Development
• 4.2 Drugs of Abuse - Pipeline Products by Stage of Development

5 Drugs of Abuse Companies and Product Overview

• 5.1 Accelerate Diagnostics Inc Company Overview
• 5.2 Adaltis Srl Company Overview
• 5.3 Banyan Biomarkers Inc Company Overview
• 5.4 Behavioral Diagnostics Inc Company Overview
• 5.5 BioMark Technologies Inc Company Overview
• 5.6 Ceres Nanosciences Inc Company Overview
• 5.7 genedrive plc Company Overview
• 5.8 Horiba Ltd Company Overview
• 5.9 OpalGenix Inc Company Overview
• 5.10 Randox Laboratories Ltd Company Overview
• 5.11 Roche Diagnostics International Ltd Company Overview
• 5.12 SDI Biomed, Inc. Company Overview
• 5.13 SensoDXII LLC Company Overview
• 5.14 Siemens Healthcare Diagnostics Inc Company Overview
• 5.15 Siemens Healthineers AG Company Overview
• 5.16 Thermo Fisher Scientific Inc Company Overview
• 5.17 University of California San Francisco Company Overview
• 5.18 ZORA Biosciences Oy Company Overview

6 Drugs of Abuse- Recent Developments

• 6.1 Sep 14, 2022: Horiba announces Review of First Half of 2022
• 6.2 Sep 06, 2022: Labcorp to Speak at the Baird 2022 Global Healthcare Conference
• 6.3 Aug 24, 2022: New line of electrochemistry bench meters simplify pH, conductivity and dissolved oxygen measurement
• 6.4 Aug 12, 2022: Horiba announce Summary of Consolidated Financial Statements for the Six Months Ended June 30, 2022
• 6.5 Aug 09, 2022: OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year
• 6.6 Jul 28, 2022: Labcorp Announces 2022 Second Quarter Results
• 6.7 May 17, 2022: Labcorp to Speak at the UBS 2022 Global Healthcare Conference
• 6.8 May 10, 2022: OraSure Reports 1Q22 Record Revenue of $67.7 Million +16% Year-Over-Year With 21% Growth in Non-COVID Revenue
• 6.9 May 04, 2022: Labcorp to Webcast Its Annual Meeting of Shareholders
• 6.10 Apr 11, 2022: Thermo Fisher Scientific to Host Investor Day
• 6.11 Mar 22, 2022: OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role
• 6.12 Feb 23, 2022: Orasure Technologies Reports 4q21 Revenue of $63.6 Million; Inteliswab® Production Scales Up
• 6.13 Feb 14, 2022: Horiba announces Summary of Consolidated Financial Statements for the Year Ended December 31, 2021
• 6.14 Feb 02, 2022: Salimetrics expands laboratory CLIA Certification for Saliva Testing
• 6.15 Jan 04, 2022: Labcorp to Speak Virtually at the 40th Annual J.P. Morgan Healthcare Conference
• 6.16 Dec 31, 2021: Improve Medical Instruments Announces on the Resignation of the Secretary of the Board of Directors and the Appointment of the Secretary of the Board of Directors
• 6.17 Nov 12, 2021: Psychemedics Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021
• 6.18 Nov 11, 2021: Horiba Announces Summary of Consolidated Financial Statements for the Nine Months Ended September 30, 2021
• 6.19 Nov 03, 2021: OraSure Technologies Reports 3Q21 Revenue of $53.9 Million
• 6.20 Nov 02, 2021: Labcorp to Speak at Credit Suisse 30th Annual Healthcare Conference

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer